Bank of Montreal Can raised its position in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 1.9% during the second quarter, Holdings Channel reports. The institutional investor owned 874,254 shares of the biopharmaceutical company’s stock after buying an additional 16,535 shares during the period. Bank of Montreal Can’s holdings in Arbutus Biopharma Corporation were worth $3,147,000 as of its most recent filing with the SEC.

Separately, Renaissance Technologies LLC increased its stake in Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the last quarter. Institutional investors own 66.53% of the company’s stock.

Arbutus Biopharma Corporation (ABUS) traded up 0.725% on Monday, reaching $3.475. 8,479 shares of the company’s stock were exchanged. The firm’s market capitalization is $191.21 million. Arbutus Biopharma Corporation has a 12 month low of $2.35 and a 12 month high of $4.49. The firm has a 50-day moving average of $3.67 and a 200-day moving average of $3.22.

Arbutus Biopharma Corporation (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $7.50 million. On average, equities analysts expect that Arbutus Biopharma Corporation will post ($1.46) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Bank of Montreal Can Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS)” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at

ABUS has been the subject of several research analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Arbutus Biopharma Corporation in a research report on Friday, June 2nd. They issued a “buy” rating and a $32.00 target price for the company. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a research report on Monday. Finally, Zacks Investment Research raised shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 10th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Arbutus Biopharma Corporation has a consensus rating of “Buy” and a consensus target price of $11.65.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Want to see what other hedge funds are holding ABUS? Visit to get the latest 13F filings and insider trades for Arbutus Biopharma Corporation (NASDAQ:ABUS).

Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with's FREE daily email newsletter.